Skip to main content
Santhosh Sadashiv, MD, Hematology, Pittsburgh, PA

SanthoshKukkadiSadashivMD

Hematology Pittsburgh, PA

Hematologic Oncology

Associate Program Director Division of Hematology and Cellular Therapy

Dr. Sadashiv is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Sadashiv's full profile

Already have an account?

  • Office

    4815 Liberty Ave
    Ste 322
    Pittsburgh, PA 15224
    Phone+1 412-578-4484
    Fax+1 412-578-3536

Education & Training

  • Allegheny Health Network Medical Education Consortium (WPH/AGH)
    Allegheny Health Network Medical Education Consortium (WPH/AGH)Fellowship, Hematology and Medical Oncology, 2011 - 2014
  • UMass Chan - Baystate
    UMass Chan - BaystateFellowship, Geriatric Medicine (Internal Medicine), 2003 - 2004
  • One Brooklyn Health System/Brookdale University Hospital and Medical Center
    One Brooklyn Health System/Brookdale University Hospital and Medical CenterResidency, Internal Medicine, 2000 - 2003
  • Siddhartha Medical College NTR
    Siddhartha Medical College NTRClass of 1998

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 2003 - 2024
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Journal Articles

  • Efficacy and tolerability of treatment with azacitidine for 5 days in elderly patients with acute myeloid leukemia.  
    Santhosh K Sadashiv, Christie Hilton, Cyrus Khan, James M Rossetti, Heather L Benjamin, Salman Fazal, Entezam Sahovic, Richard K Shadduck, and John Lister, Cancer Med. 2014 Dec; 3(6): 1570–1578., 8/16/2014
  • Efficacy and tolerability of treatment with azacitidine for 5 days in elderly patients with acute myeloid leukemia.  
    Santhosh K Sadashiv, Christie Hilton, Cyrus Khan, James M Rossetti, Heather L Benjamin, Salman Fazal, Entezam Sahovic, Richard K Shadduck, and John Lister, Cancer Med. 2014 Dec; 3(6): 1570–1578., 8/16/2014
  • Efficacy and tolerability of treatment with azacitidine for 5 days in elderly patients with acute myeloid leukemia.  
    Santhosh K Sadashiv, Christie Hilton, Cyrus Khan, James M Rossetti, Heather L Benjamin, Salman Fazal, Entezam Sahovic, Richard K Shadduck, and John Lister, Cancer Med. 2014 Dec; 3(6): 1570–1578., 8/16/2014

Abstracts/Posters

  • Autologous Stem Cell Transplantation in Multiple Myeloma Patients Older Than 65 Year-Old, 12-Years Analysis of National Cancer Database
    Santhosh Sadashiv, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Impact of Socioeconomic Factors on Timeliness of First Line Chemotherapy and Survival in Patients with Active Multiple Myeloma
    Santhosh Sadashiv, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • In-Hospital Complications and Outcomes of Autologous Stem Cell Transplantation in Multiple Myeloma Patients Older Than 65-Years Old in the United States: National Inpa...
    Santhosh Sadashiv, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

  • The Risk Factors of the Venous Thromboembolism in Hospitalized Patients with Hematologic Malignancies in the United States: National Inpatient Sample Analysis, 2011-2015 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • VTE Risk and Incidence in Hospitalized Patients with Blood Cancers
    VTE Risk and Incidence in Hospitalized Patients with Blood CancersOctober 25th, 2019
  • Doctors Making Progress in Treating Amyloidosis
    Doctors Making Progress in Treating AmyloidosisMarch 7th, 2019